Real-World check: combo cholesterol pill works in daily practice

NCT ID NCT05559606

Completed Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study observed 1,839 adults with primary high cholesterol who were prescribed a fixed-dose combination of atorvastatin and ezetimibe for 24 weeks. Researchers collected data on how well the pill lowered LDL cholesterol and tracked any safety issues. The goal was to see if this combo therapy works as well in everyday clinics as it does in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atorvastatin and ezetimibe combination pill
What this could lead to: If results are positive, this could confirm that the fixed-dose combo pill is a safe and effective option for managing high cholesterol in everyday patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only lasted 24 weeks, so long-term safety and benefits are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Severance Hospital, Yonsei University Health System

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.